Page 9 - T Cell News Today

Scientists from the German Cancer Research Center (DKFZ) and the University Medical Center Mannheim (UMM) successfully tested a new form of cellular immunotherapy against brain tumors in mice for the first time.

Researchers designed a cross-sectional study to investigate the biological underpinnings of “Long COVID”, the post-acute infection syndrome triggered by SARS-CoV-2.

Scientists researching in the United States have discovered a single, small strand of microRNA or miRNA, also called let-7, that plays a crucial role in combating cancer.

Researchers at Weill Cornell Medicine have discovered that radiation therapy combined with two types of immunotherapy-;one that boosts T cells, and another that boosts dendritic cells-;can control tumors in preclinical models of triple negative breast cancer, a cancer type that's typically resistant to immunotherapy alone.

The treatment combined adoptive T-cell therapy with a personalized cancer vaccine and was found to be safe in a small cohort of 17 patients.

A comprehensive review in Signal Transduction and Targeted Therapy delves into the versatility and effectiveness of mRNA vaccines, from their game-changing role in COVID-19 to potential applications in cancer and rare diseases. Despite drawbacks like stability and high immunogenicity, advancements in vaccine technology have poised mRNA platforms as a robust tool for both preventive and therapeutic interventions.

Study uncovers the complexities of how CD1 molecules present a vast array of lipids to T-cells, revealing a unique, size-based antigen-display system. The findings could provide crucial insights into the intricacies of immune response and antigen presentation.

Researchers have studied how the T-cell aging process translates into metabolic reprogramming of the T-cells in patients with rheumatoid arthritis.

Michel Sadelain is being awarded the Breakthrough Award in Life Sciences for his discovery of CAR T cells, which uses cells to heal cancer patients.

Researchers evaluated sensitivity to immune checkpoint blockade (ICB) therapy.